March 2022 FDA Recall Sodium Acetate by Fresenius Kabi Usa, Llc
D-0750-2022 - Presence of particulate matter

This Class I drug recall was voluntarily initiated by Fresenius Kabi Usa, Llc on March 4, 2022 for the product Sodium Acetate. The FDA reported the reason for recall as presence of particulate matter. The product was distributed Nationwide and the recall is currently terminated.

Recall Number: D-0750-2022

Reason for Recall
Presence of particulate matter: particulates composed of carbon and oxygen with varying amounts of iron and trace amounts of sodium, silicon, chromium, aluminum and cellulose.
Initiated
03-04-2022
Reported
03-30-2022
Quantity
118,040 vials

Recall Profile & Regulatory Data

Class I - is a situation in which there is a reasonable probability that the use of, or exposure to, a violative product will cause serious adverse health consequences or death.
Fresenius Kabi USA, LLC
Sodium Acetate Injection, USP, 400 mEq / 100 mL (4 mEq / mL), packaged in 2 trays of 20 vials per shipper (NDC 63323-032-00), each vial: 100 mL fill in a 100 mL vial (NDC 63323-032-04), Rx Only, Fresenius Kabi, Lake Zurich, IL 60047

Batch or Lot Expiration Information

Lot# : 6124193, 6124196, 6124226, Exp 05/2022; 6124532, Exp 06/2022; 6125333, Exp 12/2022; 6125678, Exp 01/2023; 6126846, Exp 08/2023

Affected Packages Involved in this Recall